# A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate

> **NCT00420199** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 50 (actual)

## Conditions studied

- Active Rheumatoid Arthritis

## Interventions

- **DRUG:** Abatacept
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00420199
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-05
- **Primary completion:** 2009-08
- **Final completion:** 2010-05
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2012-01-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00420199

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00420199, "A Phase IIIb Study of BMS-188667 in Subjects With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT00420199. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*